With its headquarters situated in Cranbury, New Jersey, Amicus Therapeutics is among the leading biopharmaceutical companies in America. The company was officially launched in 2007 under the FOLD trading symbol of NASDAQ. The company has since flourished in the healthcare industry following that it registered an impressive increase in revenue by 71.4% in the second quarterly year from the previous first one (Crunchbase). Before its initial public opening, Amicus Therapeutics was initially the brainchild of several venture capital firms, including Canaan Partners and New Enterprise Associates, just to mention a few.
The Institute centers its focus on diseases that are collectively called lysosomal storage disorders. They also participate in the advancement of Chaperone-Advance Replacement and enzyme replacement therapies (http://www.marketwatch.com/investing/stock/fold). Initially, the company had no marketed products, but through their first partnerships with JCR Pharmaceutical and GlaxoSmithKline, they began with the development of migalastat monotherapy. Since the institute has no capacity to manufacture its products, it simply relies on contract manufacturing.
Amicus Therapeutics’ Chief Executive Officer has been John F. Crowley ever since 2005. Mr. Crowley preceded Donald Hayden, Jr. chairman of the company’s board while Hayden was reinstated in as the Lead Independent Director.
In the company’s bid to research on rare and orphan disorders, Amicus Therapeutics has received grants from the Foundation of Alzheimer’s Drug Discovery and the Michael J. Fox Foundation. These funds were especially allocated to the research and studies of rare diseases. The company was also successful in acquiring their competitor, Callidus Biopharma, in 2013, thereby obtaining all intellectual property on the advancement of enzyme replacement therapy for Pompe disease.
The company also formulated a belief statement that defines their core values and their level of commitment towards enhancing therapies for orphan diseases. In their belief statement, they state that they firmly believe in remaining at the forefront of advancement of therapies for rare and orphan diseases.